Medivation, Inc., MDVN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Medivation, Inc., MDVN has a market cap of 13452.13. Since its IPO date on the 1/13/1997, Medivation, Inc., MDVN performance year to date is 67.81%. Today Medivation, Inc., MDVN has gained -0.09%, with a current price of 81.05.
Ownership of the company is 0.20% for insider ownership while institutional ownership is 91.30%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at -13.00%, with return on investment at 27.10%.
In terms of debt levels and profit levels, Medivation, Inc., MDVN is seeing a long-term debt/equity of 0. While Total debt/equity is 0. With a profit margin of -17.20%, this is combined with a gross margin of *TBA, and operating margin of -26.30%. Medivation, Inc. ability to meet debt levels, with a current ratio of 4.3, while the quick ratio is 4.3.
For the last year Medivation, Inc., MDVN has seen a EPS growth of -11.10%. A performance for the year of 65.67%. The 52-week high is -0.12%, and the 52-week low is 206.89%. The average volume for Medivation, Inc., MDVN is 491858.
With a target price of 77.15, can Medivation, Inc., MDVN reach this target? Looking at the value indicators of Medivation, Inc., MDVN. Medivation, Inc. has a P/E of *TBA and a forward P/E of 37.26. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Medivation, Inc. also has a P/S and a P/B of 13.1 and 25.04 respectively. For P/cash, Medivation, Inc. has a value of 41.11, while it is 44.21 for P/free cash flow.
At the current price of 81.05, Medivation, Inc. has a dividend yield of *TBA. We see a return on equity of -23.80%.
Looking more long-term Medivation, Inc., is projected to get an EPS growth for the next five years of 37.68%. In the short-term an EPS growth of 71.15% in the next year is forecasted. This is after a EPS growth of -11.10% for this year and for the last five years a 50.90% growth has been seen.